CompletedNot Applicable

Staphylococcal Acute Post-Operative PJI Treated With 'DAIR' And Impact Of Rifampin

France79 participantsStarted 2018-04-01

Plain-language summary

S. aureus and coagulase-negative staphylococci are the most frequent bacteria responsible for PJI (prosthetic joint infection). The aim of this study is to describe the use of rifampicin.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: patients having had acute PJI (i.e. \<1 month following the implantation), DAIR with exchange of removal components) due to S. aureus and coagulase-negative staphylococci (2011-2016) Exclusion Criteria: None

What they're measuring

description of the use of rifampicin : rate of use

Timeframe: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)

Trial details

NCT IDNCT03750721

SponsorHospices Civils de Lyon

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-05-01

View on ClinicalTrials.gov More Bone and Joint Infection trials